SUMO2 and neoplasm: All evaluated tumor samples demonstrated robust target engagement following subasumstat administration; SUMO2/3 inhibition was observed in most post-dose samples, except for two patients with MSS colorectal cancer and one patient with NSCLC (Fig. 3A and B).